Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s40256-020-00409-x.pdf
Reference60 articles.
1. Awtry EH, Loscalzo J. Cardiovascular drugs aspirin. Circulation. 2000;101:1206–18.
2. Rocca B, Dragani A, Pagliaccia F. Identifying determinants of variability to tailor aspirin therapy. Expert Rev Cardiovasc Ther. 2013;11:365–79.
3. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036–46.
4. The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39.
5. Caldeira D, Alves M, David C, Costa J, Ferreira JJ, Pinto FJ. Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis. Prim Care Diabetes. 2019. https://doi.org/10.1016/j.pcd.2019.11.004(Epub 30 Nov).
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?;American Journal of Hematology;2024-05-16
2. Polycythemia vera and management of the thrombotic risk: an update;Bleeding, Thrombosis, and Vascular Biology;2023-12-20
3. BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera;Physiology International;2023-09-05
4. Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2023-06-26
5. Comparison of Different Laboratory Tests to Identify “Aspirin Resistance” and Risk of Vascular Events among Ischaemic Stroke Patients: A Double-Blind Study;Journal of Cardiovascular Development and Disease;2022-05-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3